Regulatory bodies require evidence of safety, effectiveness and risk management for clinical AI products. Frameworks include premarket review, post market surveillance, and requirements for software updates and change control. Manufacturers must provide validation studies, clinical performance data, and risk mitigation plans tailored to intended use.
Regulatory compliance ensures patient safety and provides a framework for responsible clinical AI adoption. Processes and evidence required to obtain regulatory clearance and maintain post market safety for AI tools. Clinicians and health systems should verify regulatory status, understand labeled use, and monitor real world performance post deployment.
Main Points: Regulatory Pathways for Clinical AI | Premarket evidence | Intended use labeling | Change management | Post market surveillance | Risk mitigation
Quick Facts: Regulatory clearance varies by jurisdiction | Intended use defines evidence needs | Change control is critical for adaptive models | Post market data informs safety | Health systems must verify claims
Topics related to Regulatory Pathways for Clinical AI include FDA | CE marking | post market surveillance